Skip to main content
Clinical Trials/NCT04712032
NCT04712032
Unknown
Phase 3

A PHASE III, RANDOMISED CONTROLLED TRIAL ASSESSING THE VALUE OF INDOCYANINE GREEN IN THE LEAKAGE RATE OF COLORECTAL ANASTOMOSES

Leiden University Medical Center1 site in 1 country978 target enrollmentStarted: July 1, 2020Last updated:

Overview

Phase
Phase 3
Sponsor
Leiden University Medical Center
Enrollment
978
Locations
1
Primary Endpoint
90-days Anastomotic Leakage (AL) rate

Overview

Brief Summary

Anastomotic leakage (AL) is one of the major complications after gastrointestinal surgery. Compromised tissue perfusion at the anastomosis site increases the risk of AL. Indocyanine green (ICG) combined with fluorescent near infrared imaging has proven to be a feasible and reproducible application for real-time intraoperative quantification of the tissue perfusion and cohort studies showed reduced leakage rate. Unfortunately, these studies were not randomized. Therefore, we propose a nationwide randomized controlled trial to identify the value of ICG for AL in colorectal anastomosis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Participant)

Masking Description

Intraoperative imaging is unable to blind the surgeon. Patient is only blinded preoperatively.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Scheduled for laparoscopic or robotic-assisted colorectal resection with primary anastomosis;
  • Patients aged over 18 years old;
  • Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions;
  • Signed informed consent prior to any study-mandated procedure;

Exclusion Criteria

  • Known allergy or history of adverse reaction to ICG, iodine or iodine dyes;
  • Severe liver or kidney insufficiency;
  • Hyperthyroidism or a benign thyroid tumour;
  • Pregnant or breastfeeding women;
  • Scheduled for palliative surgery or terminal ill
  • Scheduled for a diverting stoma
  • Any condition that the investigator considers to be potentially jeopardizing the patients well-being or the study objectives (following a detailed medical history and physical examination;
  • Subject taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid;
  • Emergency surgery

Arms & Interventions

Image Guided Bowel Anastomosis group

Experimental

ICG-guided perfusion assessment

Intervention: ICG-guided bowel perfusion assessment (Drug)

Outcomes

Primary Outcomes

90-days Anastomotic Leakage (AL) rate

Time Frame: 90 days

Anastomotic leakage rate

Secondary Outcomes

  • days in hospital stay(90 days)
  • mortality(90 days)
  • complication rate(90 days)
  • 30-days Anastomotic Leakage ( AL) rate(30 days)

Investigators

Sponsor
Leiden University Medical Center
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alexander Vahrmeijer

Principal Investigator

Leiden University Medical Center

Study Sites (1)

Loading locations...

Similar Trials